Hepatitis Therapeutics

Hepatitis Therapeutics


Global Hepatitis Therapeutics Market to Reach US$21.1 Billion by 2030

The global market for Hepatitis Therapeutics estimated at US$16.3 Billion in the year 2023, is expected to reach US$21.1 Billion by 2030, growing at a CAGR of 3.7% over the analysis period 2023-2030. Hepatitis C Disease Type, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$17.8 Billion by the end of the analysis period. Growth in the Hepatitis B Disease Type segment is estimated at 2.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.3 Billion While China is Forecast to Grow at 5.8% CAGR

The Hepatitis Therapeutics market in the U.S. is estimated at US$4.3 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$4.4 Billion by the year 2030 trailing a CAGR of 5.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.2% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR.

Global Hepatitis Therapeutics Market - Key Trends and Drivers Summarized

How Are Hepatitis Therapeutics Advancing the Fight Against Chronic Hepatitis?

Hepatitis therapeutics have evolved significantly in recent years, providing patients with more effective treatment options for managing chronic hepatitis infections, particularly hepatitis B and C. Chronic hepatitis can lead to severe liver complications, including cirrhosis, liver failure, and liver cancer if left untreated. Therapeutic options for hepatitis include antiviral medications, immune modulators, and interferon therapies designed to reduce viral replication and prevent liver damage. The advent of direct-acting antivirals (DAAs) has revolutionized the treatment of hepatitis C, offering high cure rates and shorter treatment durations compared to previous therapies. With the ongoing development of new therapeutic agents, the hepatitis therapeutics market continues to expand, addressing the unmet needs of patients worldwide.

How Are Technological Innovations Influencing the Hepatitis Therapeutics Market?

Technological advancements in drug development and personalized medicine have significantly impacted the hepatitis therapeutics market. Direct-acting antivirals (DAAs) have transformed the treatment landscape for hepatitis C, achieving cure rates exceeding 95% in many cases. These therapies target specific proteins essential for viral replication, leading to more targeted and effective treatments with fewer side effects. Additionally, advancements in biologics and gene therapies are being explored for hepatitis B, offering new hope for achieving a functional cure, which has long eluded researchers. Improved diagnostic tools also enable personalized treatment regimens, allowing clinicians to tailor therapies based on viral genotypes, patient history, and potential drug resistance.

How Do Market Segments Influence the Hepatitis Therapeutics Industry?

Drug classes include antivirals, immune modulators, and combination therapies, with direct-acting antivirals (DAAs) leading the market due to their effectiveness in curing hepatitis C. Therapeutic types are also segmented based on the specific virus being treated—hepatitis B, C, or other variants—where hepatitis C therapies dominate, given the recent breakthroughs in antiviral treatments. Distribution channels include hospital pharmacies, retail pharmacies, and online platforms, with hospital pharmacies accounting for the largest market share due to the need for specialized treatment administration and monitoring.

What Factors Are Driving the Growth in the Hepatitis Therapeutics Market?

The growth in the hepatitis therapeutics market is driven by several factors, including the increasing prevalence of chronic hepatitis infections, the development of highly effective direct-acting antivirals (DAAs), and advancements in personalized medicine. The global burden of hepatitis, particularly hepatitis B and C, continues to drive demand for effective treatments, with millions of individuals requiring long-term management of their condition. The approval of new hepatitis C therapies, which offer shorter treatment durations and fewer side effects, has led to increased treatment rates and market growth. In addition, the development of novel therapeutic approaches, such as gene therapy and biologics, is expected to open new avenues for treating hepatitis B. The expansion of healthcare infrastructure in emerging markets and government initiatives aimed at eradicating hepatitis further support the growth of this market.

Select Competitors (Total 43 Featured) -
  • AbbVie, Inc.
  • Abivax SA
  • Bristol-Myers Squibb Company
  • Cipla, Inc.
  • Gilead
  • GlaxoSmithKline plc
  • Hetero Healthcare Ltd.
  • Hoffmann-La Roche, Ltd.
  • Johnson & Johnson
  • Laurus Ltd.
  • Merck & Co., Inc.
  • Natco Pharma Ltd.
  • Novartis AG
  • Novira Therapeutics
  • Zydus Cadila


Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Global Economic Update
Hepatitis Therapeutics – Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Prevalence of Hepatitis B and C Infections Drives Demand for Therapeutics
Technological Advancements in Antiviral Drug Development Propel Growth in Hepatitis Therapeutics
Increasing Focus on Combination Therapies Strengthens Business Case for Hepatitis Treatment
Surge in Government and Public Health Initiatives for Hepatitis Elimination Expands Market Opportunities
Growing Adoption of Direct-Acting Antivirals (DAAs) in Hepatitis C Treatment Spurs Market Growth
Rising Awareness About Hepatitis Vaccination Programs Expands Addressable Market for Preventive Therapies
Increasing Focus on Reducing Treatment Side Effects Generates Demand for Improved Hepatitis Drugs
Expansion of Access to Affordable Hepatitis Therapies in Emerging Markets Propels Market Growth
Rising Incidence of Co-Infections with Hepatitis B and HIV Generates Demand for Integrated Therapeutics
Technological Innovations in Long-Acting Injectable Therapies Spur Innovation in Hepatitis Treatment
Growing Focus on Personalized Medicine in Hepatitis Management Expands Market Opportunities
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 2: World Historic Review for Hepatitis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 3: World 16-Year Perspective for Hepatitis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for Hepatitis C by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 5: World Historic Review for Hepatitis C by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 6: World 16-Year Perspective for Hepatitis C by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 7: World Recent Past, Current & Future Analysis for Hepatitis B by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 8: World Historic Review for Hepatitis B by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 9: World 16-Year Perspective for Hepatitis B by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 10: World Recent Past, Current & Future Analysis for Hepatitis A by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 11: World Historic Review for Hepatitis A by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 12: World 16-Year Perspective for Hepatitis A by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 13: World Hepatitis Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 14: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 16: World 16-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Nucleoside Analogue Antivirals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 18: World Historic Review for Nucleoside Analogue Antivirals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 19: World 16-Year Perspective for Nucleoside Analogue Antivirals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Thrombopoiesis Stimulating Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 21: World Historic Review for Thrombopoiesis Stimulating Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 22: World 16-Year Perspective for Thrombopoiesis Stimulating Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Hepatitis C Protease / NS5A Inhibitor Combinations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 24: World Historic Review for Hepatitis C Protease / NS5A Inhibitor Combinations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 25: World 16-Year Perspective for Hepatitis C Protease / NS5A Inhibitor Combinations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Nucleotide Polymerase / NS5A Inhibitor Combinations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 27: World Historic Review for Nucleotide Polymerase / NS5A Inhibitor Combinations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 28: World 16-Year Perspective for Nucleotide Polymerase / NS5A Inhibitor Combinations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 29: World Recent Past, Current & Future Analysis for HIV NRTIs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 30: World Historic Review for HIV NRTIs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 31: World 16-Year Perspective for HIV NRTIs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 32: World Recent Past, Current & Future Analysis for NS5A Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 33: World Historic Review for NS5A Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 34: World 16-Year Perspective for NS5A Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 35: World Recent Past, Current & Future Analysis for Nucleotide Polymerase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 36: World Historic Review for Nucleotide Polymerase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 37: World 16-Year Perspective for Nucleotide Polymerase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 38: World Recent Past, Current & Future Analysis for Interferon Alphas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 39: World Historic Review for Interferon Alphas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: World 16-Year Perspective for Interferon Alphas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Hepatitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 41: USA Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 42: USA Historic Review for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: USA 16-Year Perspective for Hepatitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 44: USA Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: USA Historic Review for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: USA 16-Year Perspective for Hepatitis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas for the Years 2014, 2024 & 2030
CANADA
TABLE 47: Canada Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 48: Canada Historic Review for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: Canada 16-Year Perspective for Hepatitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 50: Canada Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 51: Canada Historic Review for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: Canada 16-Year Perspective for Hepatitis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas for the Years 2014, 2024 & 2030
JAPAN
Hepatitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 53: Japan Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 54: Japan Historic Review for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: Japan 16-Year Perspective for Hepatitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 56: Japan Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 57: Japan Historic Review for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: Japan 16-Year Perspective for Hepatitis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas for the Years 2014, 2024 & 2030
CHINA
Hepatitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 59: China Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 60: China Historic Review for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 61: China 16-Year Perspective for Hepatitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 62: China Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: China Historic Review for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 64: China 16-Year Perspective for Hepatitis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas for the Years 2014, 2024 & 2030
EUROPE
Hepatitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 65: Europe Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 66: Europe Historic Review for Hepatitis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 67: Europe 16-Year Perspective for Hepatitis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 68: Europe Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 69: Europe Historic Review for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 70: Europe 16-Year Perspective for Hepatitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 71: Europe Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 72: Europe Historic Review for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 73: Europe 16-Year Perspective for Hepatitis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas for the Years 2014, 2024 & 2030
FRANCE
Hepatitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 74: France Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 75: France Historic Review for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 76: France 16-Year Perspective for Hepatitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 77: France Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 78: France Historic Review for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 79: France 16-Year Perspective for Hepatitis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas for the Years 2014, 2024 & 2030
GERMANY
Hepatitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 80: Germany Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 81: Germany Historic Review for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 82: Germany 16-Year Perspective for Hepatitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 83: Germany Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 84: Germany Historic Review for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 85: Germany 16-Year Perspective for Hepatitis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas for the Years 2014, 2024 & 2030
ITALY
TABLE 86: Italy Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: Italy Historic Review for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 88: Italy 16-Year Perspective for Hepatitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 89: Italy Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 90: Italy Historic Review for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 91: Italy 16-Year Perspective for Hepatitis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas for the Years 2014, 2024 & 2030
UNITED KINGDOM
Hepatitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 92: UK Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 93: UK Historic Review for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 94: UK 16-Year Perspective for Hepatitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 95: UK Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 96: UK Historic Review for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 97: UK 16-Year Perspective for Hepatitis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas for the Years 2014, 2024 & 2030
SPAIN
TABLE 98: Spain Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 99: Spain Historic Review for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 100: Spain 16-Year Perspective for Hepatitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 101: Spain Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 102: Spain Historic Review for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 103: Spain 16-Year Perspective for Hepatitis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas for the Years 2014, 2024 & 2030
RUSSIA
TABLE 104: Russia Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 105: Russia Historic Review for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 106: Russia 16-Year Perspective for Hepatitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 107: Russia Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 108: Russia Historic Review for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 109: Russia 16-Year Perspective for Hepatitis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 111: Rest of Europe Historic Review for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 112: Rest of Europe 16-Year Perspective for Hepatitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 113: Rest of Europe Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 114: Rest of Europe Historic Review for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 115: Rest of Europe 16-Year Perspective for Hepatitis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Hepatitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 117: Asia-Pacific Historic Review for Hepatitis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 118: Asia-Pacific 16-Year Perspective for Hepatitis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
TABLE 119: Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 120: Asia-Pacific Historic Review for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 121: Asia-Pacific 16-Year Perspective for Hepatitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 123: Asia-Pacific Historic Review for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 124: Asia-Pacific 16-Year Perspective for Hepatitis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas for the Years 2014, 2024 & 2030
AUSTRALIA
Hepatitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
TABLE 125: Australia Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 126: Australia Historic Review for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 127: Australia 16-Year Perspective for Hepatitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 128: Australia Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 129: Australia Historic Review for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 130: Australia 16-Year Perspective for Hepatitis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas for the Years 2014, 2024 & 2030
INDIA
Hepatitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
TABLE 131: India Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 132: India Historic Review for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 133: India 16-Year Perspective for Hepatitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 134: India Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 135: India Historic Review for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 136: India 16-Year Perspective for Hepatitis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas for the Years 2014, 2024 & 2030
SOUTH KOREA
TABLE 137: South Korea Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 138: South Korea Historic Review for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 139: South Korea 16-Year Perspective for Hepatitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 140: South Korea Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 141: South Korea Historic Review for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 142: South Korea 16-Year Perspective for Hepatitis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
TABLE 143: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 144: Rest of Asia-Pacific Historic Review for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 145: Rest of Asia-Pacific 16-Year Perspective for Hepatitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 146: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 147: Rest of Asia-Pacific Historic Review for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 148: Rest of Asia-Pacific 16-Year Perspective for Hepatitis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas for the Years 2014, 2024 & 2030
LATIN AMERICA
Hepatitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
TABLE 149: Latin America Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 150: Latin America Historic Review for Hepatitis Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 151: Latin America 16-Year Perspective for Hepatitis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
TABLE 152: Latin America Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 153: Latin America Historic Review for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 154: Latin America 16-Year Perspective for Hepatitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 155: Latin America Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 156: Latin America Historic Review for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 157: Latin America 16-Year Perspective for Hepatitis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas for the Years 2014, 2024 & 2030
ARGENTINA
TABLE 158: Argentina Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 159: Argentina Historic Review for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 160: Argentina 16-Year Perspective for Hepatitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 161: Argentina Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 162: Argentina Historic Review for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 163: Argentina 16-Year Perspective for Hepatitis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas for the Years 2014, 2024 & 2030
BRAZIL
TABLE 164: Brazil Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 165: Brazil Historic Review for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 166: Brazil 16-Year Perspective for Hepatitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 167: Brazil Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 168: Brazil Historic Review for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 169: Brazil 16-Year Perspective for Hepatitis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas for the Years 2014, 2024 & 2030
MEXICO
TABLE 170: Mexico Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 171: Mexico Historic Review for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 172: Mexico 16-Year Perspective for Hepatitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 173: Mexico Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 174: Mexico Historic Review for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 175: Mexico 16-Year Perspective for Hepatitis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
TABLE 176: Rest of Latin America Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 177: Rest of Latin America Historic Review for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 178: Rest of Latin America 16-Year Perspective for Hepatitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 179: Rest of Latin America Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 180: Rest of Latin America Historic Review for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 181: Rest of Latin America 16-Year Perspective for Hepatitis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas for the Years 2014, 2024 & 2030
MIDDLE EAST
Hepatitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
TABLE 182: Middle East Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 183: Middle East Historic Review for Hepatitis Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 184: Middle East 16-Year Perspective for Hepatitis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
TABLE 185: Middle East Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 186: Middle East Historic Review for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 187: Middle East 16-Year Perspective for Hepatitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 188: Middle East Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 189: Middle East Historic Review for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 190: Middle East 16-Year Perspective for Hepatitis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas for the Years 2014, 2024 & 2030
IRAN
TABLE 191: Iran Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 192: Iran Historic Review for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 193: Iran 16-Year Perspective for Hepatitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 194: Iran Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 195: Iran Historic Review for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 196: Iran 16-Year Perspective for Hepatitis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas for the Years 2014, 2024 & 2030
ISRAEL
TABLE 197: Israel Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 198: Israel Historic Review for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 199: Israel 16-Year Perspective for Hepatitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 200: Israel Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 201: Israel Historic Review for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 202: Israel 16-Year Perspective for Hepatitis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas for the Years 2014, 2024 & 2030
SAUDI ARABIA
TABLE 203: Saudi Arabia Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 204: Saudi Arabia Historic Review for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 205: Saudi Arabia 16-Year Perspective for Hepatitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 206: Saudi Arabia Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 207: Saudi Arabia Historic Review for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 208: Saudi Arabia 16-Year Perspective for Hepatitis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
TABLE 209: UAE Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 210: UAE Historic Review for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 211: UAE 16-Year Perspective for Hepatitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 212: UAE Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 213: UAE Historic Review for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 214: UAE 16-Year Perspective for Hepatitis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
TABLE 215: Rest of Middle East Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 216: Rest of Middle East Historic Review for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 217: Rest of Middle East 16-Year Perspective for Hepatitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 218: Rest of Middle East Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 219: Rest of Middle East Historic Review for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 220: Rest of Middle East 16-Year Perspective for Hepatitis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas for the Years 2014, 2024 & 2030
AFRICA
Hepatitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
TABLE 221: Africa Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 222: Africa Historic Review for Hepatitis Therapeutics by Disease Type - Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 223: Africa 16-Year Perspective for Hepatitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis C, Hepatitis B, Hepatitis A and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 224: Africa Recent Past, Current & Future Analysis for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 225: Africa Historic Review for Hepatitis Therapeutics by Drug Class - Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 226: Africa 16-Year Perspective for Hepatitis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents, Hepatitis C Protease / NS5A Inhibitor Combinations, Nucleotide Polymerase / NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Interferon Alphas for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings